Rationale and design of a digital trial using smartphones to detect subclinical atrial fibrillation in a population at risk: The eHealth-based bavarian alternative detection of Atrial Fibrillation (eBRAVE-AF) trial.
Asymptomatic Diseases
/ epidemiology
Atrial Fibrillation
/ complications
Cross-Over Studies
Female
Germany
/ epidemiology
Humans
Insurance, Health
/ statistics & numerical data
Male
Middle Aged
Mobile Applications
Monitoring, Ambulatory
/ instrumentation
Randomized Controlled Trials as Topic
/ methods
Smartphone
Telemedicine
/ instrumentation
Journal
American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
27
01
2021
accepted:
20
06
2021
pubmed:
13
7
2021
medline:
25
2
2023
entrez:
12
7
2021
Statut:
ppublish
Résumé
Current guidelines recommend opportunistic screening for subclinical atrial fibrillation (AF) taking advantage of e-health-based technologies. However, the efficacy of a fully scalable e-health-based strategy for AF detection in a head-to-head comparison with routine symptom-based screening is unknown. eBRAVE-AF is an investigator-initiated, digital, prospective, randomized, siteless, open-label, cross-over study to evaluate an e-health-based strategy for detection of AF in a real-world setting. 67,488 policyholders of a large German health insurance company (Versicherungskammer Bayern, Germany) selected by age ≥ 50 years and a CHA
Identifiants
pubmed: 34252387
pii: S0002-8703(21)00164-2
doi: 10.1016/j.ahj.2021.06.008
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04250220']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26-34Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.